Exploring the mechanism of Saposhnikoviae Radix and Chuanxiong Rhizoma treating Parkinson's disease based on network pharmacology and molecular docking

Backgroud:Parkinson’s disease(PD)is a neurodegenerative disorder with an increasing global prevalence.However,the development of drugs for PD treatment has not kept pace with the continuously growing number of patients.Currently,the search for new effective substances from natural drugs is a major research direction.Two Chinese medicinal materials,Saposhnikoviae Radix(Fangfeng)and Chuanxiong Rhizoma(Chuanxiong),are commonly used in the treatment of PD in China.However,the mechanism of their combination is not clear,and further research is needed.Methods:Data were collected from publicly available databases:TCMSP,UnitProt,GeneCards OMIM,PharmGKB,Therapeutic Target Database and DrugBank.Network pharmacology and molecular docking methods was used to analyze the data to discover the possible pharmacological effects of the two drugs in the treatment of PD.Results:Beta-sitosterol,Mandenol and Wallichilide were the active components of Saposhnikoviae Radix and Chuanxiong Rhizoma(FC),and they stably bonded with PD targets,including PTGS2,CASP3,AKT1 and JUN.The target genes of FC were significantly enriched in PD-associated pathways,including calcium signaling and apoptosis pathways.Moreover,the study revealed that the active components of FC may affect cellular structures,such as membrane rafts,membrane microdomains,membrane regions,and postsynaptic membranes,which,in turn,affect a variety of molecular functions and biological processes.Conclusion:The results of this study indicate the direction for clarifying the pharmacodynamic substances of FC,the extraction method of pharmacodynamic substances,as well as the mechanism and efficacy of pharmacodynamic substances.Importantly,this study provides a strategy for developing new therapeutic drugs for PD.

Meta-analysis of the efficacy and safety of rhbnp in the treatment of acute myocardial infarction with heart failure

Objective:Systematic review of the efficacy and safety of neoactivin re-acute myocardial infarction with heart failure.Methods:The computer retrieved CNKI,Wan Fang,Weipu Chinese Science and Technology Periodicals Database(VIP),China Biomedical Literature Database(CBM),Medline,Cochrane Library,and Clinical Trail.Gov collected clinical randomized controlled trials(RCTs)of neoactivin in the treatment of acute myocardial infarction with heart failure from the establishment of the database to December 2019.Data were extracted according to the Jadad scale,disease inclusion and exclusion criteria,and RevMan 5.3 software was used for Meta analysis.Results:A total of 23 RCTs were included,with a total of 2024 patients,including 1012 patients in the control group(conventional treatment with western medicine)and 1012 patients in the test group(on the basis of the control group+neoactivin treatment).Meta analysis results show that:in the total effective rate,the test group was better than the control group,and the difference was statistically significant(OR=4.30,95%CI[3.26,5.67],P<0.00001);In terms of left ventricular ejection fraction,the test group was better than the control group,and the difference was statistically significant(OR=1.58,95%CI[1.27,1.90],P<0.00001).In terms of the left ventricular end-diastolic diameter,the test group was better than the control group,with a statistical difference Significance(OR=-0.91,95%CI[-1.50,-0.33],P=0.002);In terms of stroke volume,the test group was better than the control group,and the difference was statistically significant(OR=1.24,95%CI[0.55,1.94],P=0.0005);In terms of brain natriuretic peptide precursors,the experimental group was better than the control group,the difference was statistically significant(OR=-4.37,95%CI[-6.21,-3.25],P<0.00001);In terms of heart rate,the test group was better than the control group,and the difference was statistically significant(OR=-13.70,95%CI[-14.95,-12.46],P<0.00001);In terms of systolic blood pressure,the test group was better than the control Group,the difference was statistically significant(OR=-12.38,95%CI[-17.98,-6.79],P<0.00001);In diastolic blood pressure,the test group was better than the control group Group,the difference was statistically significant(OR=-7.42,95%CI[-8.53,-6.30],P<0.00001);In terms of adverse reactions,the difference was not statistically significant(OR=0.95,95%CI[0.29,3.16],P=0.94).Conclusions:In patients with acute myocardial infarction and heart failure,the timely application of neoactivin treatment can improve clinical efficacy,improve cardiac function,inhibit ventricular remodeling,improve blood pressure and heart rate,which has good clinical efficacy and safety.

Ultrasensitive Detection of Hepatitis C Virus DNA Subtypes Based on Cucurbituril and Graphene Oxide Nano-composite

Infectious of hepatitis C viruses(HCVs)lead to hepatic fibrosis,cirrhosis even hepatoma.Developing rapid and sensitive diagnostic method for HCV is of great importance.Based on the host-and-guest interaction between cucurbit[7]uril(CB[7])and methylene blue(MB),a CB[7]-graphene nano-composite(CB[7]-N3-GO)is raised for the electrochemical detection of HCV DNA.The method is able to linearly detect the HCV nucleic acid in the range of 0.2—10 nmol/L with detection limit as low as 160.4 pmol/L.The proposed detection strategy is able to discriminate the lb and 6k subtypes of HCV and has a prospective potential in the blood screen for HCV in clinical diagnosis.